Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMAK1ME)

• Drug Name: CAR-T cells targeting CD56 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Multiple myeloma	2A83	Clinical trial	[1]
Acute myeloid leukaemia	2A60	Preclinical	[2]

• Cross-matching ID: TTD Drug ID: DMAK1ME

Molecule-Related Drug Atlas

Drug(s) Targeting Neural cell adhesion molecule 1 (NCAM1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CD56-specific gene-engineered T cells	DM35XCT	Acute myeloid leukaemia	2A60	Phase 1/2	[3]
CD56 CAR T cells	DMS5OL0	Multiple myeloma	2A83	Phase 1/2	[4]
CART-56 cells	DMQTOBF	Acute myeloid leukaemia	2A60	Phase 1	[5]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Neural cell adhesion molecule 1 (NCAM1)	TTVXPHT	NCAM1_HUMAN	CAR-T-Cell-Therapy	[2]

References

• [1] ClinicalTrials.gov (NCT03473496) CAR-T Cells Therapy in Relapsed/Refractory Multiple Myeloma
• [2] ClinicalTrials.gov (NCT03473457) CAR-T Cells Therapy in Relapsed/Refractory Acute Myeloid Leukemia
• [3] ClinicalTrials.gov (NCT03222674) Multi-CAR T Cell Therapy for Acute Myeloid Leukemia
• [4] ClinicalTrials.gov (NCT03271632) Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma
• [5] ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS